arrow
F

Filippo Bellati

sapienza university rome
H指数:38
被引数:4,198

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-PD1 therapies induce an early expansion of Ki67+CD8+ T cells in metastatic non-oncogene addicted NSCLC patients

Anti-PD1疗法在转移性非癌基因依赖的NSCLC患者中诱导Ki67 CD8 T细胞的早期扩增

2024-12-180
OAAI
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

CD137和调节性T细胞作为接受免疫治疗的晚期非癌基因依赖性NSCLC患者的独立预后因素

2024-04-034
OAAI
Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Parp抑制剂在原发性和复发性卵巢癌中的应用: 12项II/III期随机对照试验的荟萃分析

2020-07-0138
PREAI
Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets

基于贝伐单抗的化疗通过促进效应T细胞亚群的募集,触发了多治疗复发性卵巢癌患者的免疫效应

2019-03-1827
OAAI
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)

高级别浆液性卵巢癌患者的BRCA1基因启动子甲基化状态-卵巢癌肿瘤库 (TOC) 和卵巢癌诊断联盟 (OVCAD) 的研究

2014-08-0182
PREAI